| Viral suppression | ART adherence | ||
---|---|---|---|---|
Unadjusted OR (95% CI) | Adjusted OR (95% CI) | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | |
Support group attendance | ||||
 No | Ref | – | Ref | – |
 Yes | 0.99 (0.97–1.01) | 0.99 (0.97–1.01) | 1.02 (1.00–1.05) | 1.01 (1.00–1.03) |
Study site | ||||
 Kayunga, Uganda | Ref | – | Ref | – |
 South Rift Valley, Kenya | 0.96 (0.95–0.98) | 0.97 (0.94–0.99) | 1.18 (1.14–1.21) | 1.14 (1.10–1.18) |
 Kisumu West, Kenya | 0.97 (0.95–0.99) | 0.98 (0.95–1.01) | 1.11 (1.07–1.15) | 1.09 (1.05–1.13) |
 Mbeya, Tanzania | 0.90 (0.88–0.92) | 0.91 (0.88–0.94) | 1.06 (1.02–1.10) | 1.05 (1.01–1.10) |
 Abuja & Lagos Nigeria | 0.92 (0.88–0.96) | 0.92 (0.87–0.96) | 0.89 (0.83–0.95) | 0.88 (0.82–0.94) |
Age (years) | ||||
 18–29 | Ref | – | Ref | – |
 30–39 | 1.03 (1.00–1.05) | 1.02 (1.00–1.05) | 1.04 (1.01–1.08) | 1.03 (1.00–1.07) |
 40–49 | 1.06 (1.03–1.08) | 1.06 (1.03–1.08) | 1.08 (1.05–1.12) | 1.06 (1.03–1.10) |
 50+ | 1.06 (1.03–1.09) | 1.06 (1.03–1.10) | 1.09 (1.05–1.13) | 1.06 (1.02–1.10) |
Sex | ||||
 Male | Ref | – | Ref | – |
 Female | 1.02 (1.00–1.03) | 1.03 (1.01–1.05) | 1.01 (0.98–1.03) | 1.01 (0.99–1.03) |
Education | ||||
 None or some primary | Ref | – | Ref | – |
 Primary or some secondary | 0.98 (0.96–0.99) | 1.00 (0.98–1.01) | 1.01 (1.00–1.03) | 1.01 (0.99–1.03) |
 Secondary and above | 0.96 (0.94–0.98) | 0.99 (0.97–1.01) | 1.00 (0.97–1.02) | 1.01 (0.99–1.03) |
Currently employed | ||||
 No | Ref | – | Ref | – |
 Yes | 1.02 (1.01–1.03) | 1.01 (0.99–1.03) | 0.94 (0.93–0.96) | 1.00 (0.98–1.02) |
Marital status | ||||
 Not married | Ref | – | Ref | – |
 Married | 1.01 (1.00–1.03) | 1.01 (1.00–1.03) | 1.01 (1.00–1.03) | 1.01 (0.99–1.03) |
Consume alcohol | ||||
 No | Ref | – | Ref | – |
 Yes | 0.98 (0.96–1.00) | 1.00 (0.98–1.02) | 0.89 (0.86–0.92) | 0.90 (0.87–0.93) |
ART treatment supporter | ||||
 No | Ref | – | Ref | – |
 Yes | 1.01 (1.00–1.02) | 1.00 (0.99–1.01) | 1.01 (1.00–1.03) | 1.00 (0.99–1.02) |
WHO stage at time of HIV diagnosis | ||||
 I | Ref | – | Ref | – |
 II | 0.99 (0.98–1.01) | 0.99 (0.97–1.01) | 0.99 (0.96–1.01) | 1.00 (0.98–1.03) |
 III | 0.97 (0.95–0.99) | 0.97 (0.94–0.99) | 1.03 (1.01–1.06) | 1.02 (1.00–1.05) |
 IV | 0.99 (0.95–1.03) | 0.98 (0.94–1.03) | 1.08 (1.04–1.12) | 1.07 (1.03–1.10) |
 Unknown | 0.96 (0.89–1.04) | 0.96 (0.88–1.04) | 1.07 (1.01–1.12) | 1.04 (0.99–1.09) |
Duration on ART | ||||
  < 6 months | Ref | – | Ref | – |
 6 months to < 2 years | 0.99 (0.97–1.01) | 0.99 (0.97–1.01) | 1.02 (0.97–1.06) | 1.01 (0.97–1.05) |
 2 to < 4 years | 1.01 (0.98–1.03) | 1.00 (0.98–1.02) | 1.04 (1.00–1.08) | 1.02 (0.98–1.07) |
 4+ years | 1.00 (0.98–1.03) | 0.99 (0.96–1.01) | 1.08 (1.03–1.12) | 1.05 (1.00–1.09) |
ART regimen | ||||
 AZT/NVP/3TC | 0.97 (0.94–0.99) | 0.97 (0.95–0.99) | 0.97 (0.94–0.99) | 0.97 (0.95–0.99) |
 AZT/EFV/3TC | 1.00 (0.97–1.03) | 1.00 (0.97–1.03) | 0.97 (0.94–1.01) | 0.97 (0.93–1.00) |
 TDF/NVP/3TC | 0.98 (0.95–1.01) | 0.97 (0.95–1.00) | 1.00 (0.97–1.03) | 0.99 (0.96–1.02) |
 PI-based | 1.20 (1.15–1.26) | 1.19 (1.14–1.24) | 1.02 (0.98–1.05) | 1.00 (0.97–1.04) |
 TLE | 0.99 (0.98–1.01) | 0.99 (0.98–1.01) | 0.98 (0.96–1.00) | 1.00 (0.98–1.03) |
 Other | Ref | – | Ref | – |